Home » January /February 2023 » Enhancing patient outcomes: Strategies for a post-pandemic Life Sciences sector
2023 | January /February 2023

Enhancing patient outcomes: Strategies for a post-pandemic Life Sciences sector

by cyb2025
F. Stulp
clinical trial Information System
Clinical trials
data governance
data transformation
IDMP
life sciences
Pharma Supply Chain

FRITS STULP
Managing director of Iperion – a Deloitte business, Amsterdam, the Netherlands

ABSTRACT

Life Sciences organisations have had to rapidly adapt to a new landscape of operations. The challenges of the pandemic have put an urgent focus on enhancing patient outcomes by improving products delivery processes. In 2023 Life Sciences companies must develop strategies to capitalise on the opportunities that data-driven technologies offer. Frits Stulp of Iperion – a Deloitte business – predicts a new wave of data-based transformation as the drive to reduce time to market and address product shortages continues.

Last year was another challenging one for the Life Sciences industry. On top of residual pandemic-related challenges and supply chain issues, the ever-adapting Regulatory environment has continued to set new standards and enforce new requirements. Those companies that have managed to keep pace with the changes can expect to start reaping some of the rewards of their efforts over the coming year. Others still have work to do, but as new waves of digital transformation promise new process efficiency burdens should start to reduce and improved patient experiences will gradually become a reality.

ABOUT THE AUTHOR

Frits Stulp is managing director of Iperion – a Deloitte business, and Life Sciences partner within Deloitte where he leads a team of regulatory/IDMP experts to deliver value to both pharma companies as well as regulators. With a background as Program Manager and Advisor in information management, process design and regulatory compliance, he is an expert in the implementation of both XEVMPD and ISO IDMP requirements and the digitalization of regulatory data and processes. Frits works within the broader Life Sciences/risk division of Deloitte in the Netherlands. This article combines the latest opinions and insights from across that team.

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login